GlassScriptPhysician profile
Ramprasad Gadi
NPI 1174550461
$2,716.08
in general payments reported to CMS, 2019-2025
22 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $288 · 2021: $137 · 2022: $67.35 · 2023: $405 · 2024: $283 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.91 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $313.44 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $288.08 | 2019-2025 | |
| Amgen INC. | $226.77 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $192.25 | 2023-2024 | Watchman Flx |
| Biotronik INC. | $187.99 | 2019-2025 | |
| Zoll Respicardia, INC. | $148.43 | 2023 | Remede System |
| Novo Nordisk INC | $126.35 | 2019-2025 | Wegovy, Ozempic |
| Amarin Pharma, INC. | $115.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $103.68 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $92.30 | 2019-2025 | |
| Scpharmaceuticals INC. | $85.99 | 2024-2025 | |
| Akcea Therapeutics, INC. | $70.49 | 2019 | |
| Bardy Diagnostics, INC. | $50.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.71 | 2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $39.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.09 | 2019 | |
| Acarix USA INC. | $22.98 | 2023 | Cadscor System |
| Lilly USA, LLC | $21.55 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $20.59 | 2025 | Inspire |
| Baxter Healthcare | $20.33 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.71 | 2019-2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramprasad Gadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.